source
- Pharma leaders turn to integrated scenario modeling as US MFN pricing reshapes global launch strategiesThe article explains that integrated scenario modeling is becoming a key tool for pharmaceutical executives facing pricing uncertainty and the complexities of worldwide product launches. It refere…
- Biossil Labs acquires Theriva's antibiotic-degrader portfolio in up to $91 million dealBiossil Labs, a Canadian biotech backed by OpenAI, announced a deal to acquire Theriva Biologics' early- to mid-stage portfolio of antibiotic‑degrading enzymes for a total potential value of up to…